Moving Away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE) - Agents That Concern Prescribers and Patients: A Feasibility Study and Call for a Trial

OBJECTIVES: Regimens sparing RATE (ritonavir, abacavir, tenofovir, efavirienz) agents might have better long-term safety. We conducted a feasibility exercise to assess the potential for a randomised trial evaluating RATE-sparing regimens. DESIGN: Observational. METHODS: We first calculated RATE-spar...

Descripción completa

Detalles Bibliográficos
Autores principales: Achhra, Amit C., Boyd, Mark A., Law, Matthew G., Matthews, Gail V., Kelleher, Anthony D., Cooper, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072535/
https://www.ncbi.nlm.nih.gov/pubmed/24968324
http://dx.doi.org/10.1371/journal.pone.0099530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072535/
https://www.ncbi.nlm.nih.gov/pubmed/24968324
http://dx.doi.org/10.1371/journal.pone.0099530

Ejemplares similares